Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Raw Materials (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Raw Materials for 4 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Raw Materials rose 5.77% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 5.77% increase, with the full-year FY2024 number at $794000.0, down 13.6% from a year prior.
  • Raw Materials was $1.1 million for Q3 2025 at Gyre Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.2 million in Q2 2025 to a low of $724000.0 in Q1 2024.
  • A 4-year average of $1.0 million and a median of $1.1 million in 2022 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: fell 13.6% in 2024, then skyrocketed 61.46% in 2025.
  • Gyre Therapeutics' Raw Materials stood at $1.1 million in 2022, then decreased by 12.97% to $919000.0 in 2023, then decreased by 13.6% to $794000.0 in 2024, then soared by 38.41% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Raw Materials are $1.1 million (Q3 2025), $1.2 million (Q2 2025), and $1.2 million (Q1 2025).